Humana Inc. $HUM Shares Purchased by ProShare Advisors LLC

ProShare Advisors LLC raised its position in Humana Inc. (NYSE:HUM) by 32.0% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 27,602 shares of the insurance provider’s stock after acquiring an additional 6,688 shares during the period. ProShare Advisors LLC’s holdings in Humana were worth $6,748,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the company. Cary Street Partners Investment Advisory LLC raised its position in shares of Humana by 63.9% during the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider’s stock valued at $31,000 after buying an additional 46 shares during the period. Zions Bancorporation National Association UT purchased a new position in Humana in the first quarter worth approximately $37,000. CVA Family Office LLC increased its stake in Humana by 63.4% during the second quarter. CVA Family Office LLC now owns 219 shares of the insurance provider’s stock worth $54,000 after acquiring an additional 85 shares during the last quarter. Ransom Advisory Ltd purchased a new stake in Humana in the first quarter valued at $66,000. Finally, Transamerica Financial Advisors LLC raised its holdings in Humana by 1,027.6% in the 1st quarter. Transamerica Financial Advisors LLC now owns 327 shares of the insurance provider’s stock valued at $87,000 after buying an additional 298 shares during the period. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Stock Down 1.1%

Shares of NYSE HUM opened at $240.86 on Thursday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.95. Humana Inc. has a 1 year low of $206.87 and a 1 year high of $315.35. The business has a 50-day moving average of $273.96 and a two-hundred day moving average of $258.38. The company has a market capitalization of $28.97 billion, a price-to-earnings ratio of 18.49, a price-to-earnings-growth ratio of 1.71 and a beta of 0.42.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, November 5th. The insurance provider reported $3.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.95 by $0.29. Humana had a net margin of 1.28% and a return on equity of 13.67%. The business had revenue of $32.65 billion during the quarter, compared to analysts’ expectations of $31.99 billion. During the same quarter in the prior year, the business posted $4.16 EPS. The company’s revenue for the quarter was up 11.1% on a year-over-year basis. On average, analysts forecast that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.5%. The ex-dividend date is Friday, December 26th. Humana’s dividend payout ratio (DPR) is currently 33.18%.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Sanford C. Bernstein increased their price objective on shares of Humana from $269.00 to $341.00 and gave the stock an “outperform” rating in a research report on Friday, September 5th. Barclays decreased their price target on Humana from $315.00 to $245.00 and set an “equal weight” rating on the stock in a research note on Friday, October 3rd. Guggenheim restated a “buy” rating on shares of Humana in a research report on Friday, October 3rd. Piper Sandler cut their price objective on Humana from $288.00 to $272.00 and set a “neutral” rating on the stock in a report on Thursday, July 31st. Finally, Bank of America lifted their target price on Humana from $280.00 to $300.00 and gave the company a “neutral” rating in a research report on Friday, October 10th. Eight investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $298.39.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.